Short Interest in Grifols, S.A. (NASDAQ:GRFS) Declines By 6.5% (2024)

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 7,570,000 shares, a decrease of 6.5% from the July 15th total of 8,100,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 2.9% of the company's shares are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GRFS. Cohen Investment Advisors LLC bought a new position in shares of Grifols during the 1st quarter worth $80,000. AQR Capital Management LLC bought a new position in Grifols during the 2nd quarter worth about $89,000. Cetera Advisors LLC purchased a new position in Grifols during the 1st quarter valued at about $147,000. China Universal Asset Management Co. Ltd. increased its position in Grifols by 66.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company's stock valued at $157,000 after purchasing an additional 9,350 shares during the period. Finally, Morningstar Investment Services LLC bought a new stake in shares of Grifols in the 4th quarter valued at about $186,000.

Grifols Trading Up 1.7 %

Shares of GRFS stock traded up $0.12 on Monday, reaching $7.18. 2,432,728 shares of the company's stock were exchanged, compared to its average volume of 2,186,000. The company's fifty day simple moving average is $7.38 and its 200 day simple moving average is $7.25. The stock has a market capitalization of $4.94 billion, a PE ratio of 7.08 and a beta of 0.49. The company has a current ratio of 1.68, a quick ratio of 1.29 and a debt-to-equity ratio of 1.06. Grifols has a 52 week low of $5.30 and a 52 week high of $12.15.

Grifols (NASDAQ:GRFS - Get Free Report) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion for the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. As a group, analysts forecast that Grifols will post 0.79 EPS for the current year.

Grifols Company Profile

(Get Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Read More

• Five stocks we like better than Grifols
• Stock Analyst Ratings and Canadian Analyst Ratings
• Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
• What is the Hang Seng index?
• 2 Option Strategies to Maximize Profits in a Bear Market
• 3 Tickers Leading a Meme Stock Revival
• Lululemon Stock Gears Up for a Massive Comeback Rally

Should you invest $1,000 in Grifols right now?

Before you consider Grifols, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.

While Grifols currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here